Real-world data from the four corners of the world to power your real-world evidence (RWE) studies
At Oracle Life Sciences, we turn a sea of data into actionable evidence

Real-world evidence can be crucial to decision making when used in conjunction with clinical trials and other research activities. At Oracle Life Sciences, we turn a sea of data into actionable evidence, aimed to help you:

— Healthcare resource use
— Evaluate effectiveness and safety
— Define and understand patient subpopulations, including patients with rare diseases
— Describe and quantify patient characteristics
— Understand and define patient and disease pathways, including treatment patterns
— Compare patient cohorts longitudinally
— Assess burden of disease
— Stratify risk among patient groups
— Track progress of new drug launches

As a leader in healthcare and life sciences, our approach is data-agnostic, helping you find the right data to fit your study requirements. With access to data in more than 10 different countries, we can support you in conducting multi-country studies in some of the most important markets, including North America, LATAM, Europe and UK, Japan and Asia-Pacific countries, Middle East.
Comprehensive real-world view of patients

United States

Oracle EHR Real-world Data
By having access to an EHR dataset with over 108m patients across multiple venues of care, we can analyze patient data and understand the patient’s journey in order to uncover insights and produce evidence across a wealth of clinical metrics. Ultimately, the goal is to generate more compelling real-world evidence to support your value proposition.

— Because of the dataset size, we can perform evidence generation for rare diseases and very targeted patient populations.
— We can support studies where the clinical detail only found in the EHR is critical to the study.
— We can support the whole patient journey by tracking the patient and their clinical details across outpatient, emergency room, and inpatient encounters.
— You can now provide evidence beyond standard claims studies by using clinical data as part of your analysis.
— The EHR has critical information for social determinants of health studies, such as race, ethnicity, and marital status.

Oracle Life Sciences claims data
Through collaboration with one of the largest providers of closed claims data, Oracle Life Sciences can perform claims studies across all sizes of cohorts.
— With over 150m patients, studies can be performed on the rarest of diseases.
— With an average of over 4.3 years of enrollment per patient, studies can see more of a patient’s journey with a disease.
— Healthcare resource use and cost data for burden of illness analysis can be performed.

Oracle Life Sciences Linked Data
By linking our EHR and claims datasets at the patient level, we have over 28m patients with both claims and EHR data. This dataset gives life science clients an analytical tool that provides remarkable clarity about the patient than looking at EHR and claims data separately.
— Linking EHR and claims supports evidence that may not have been uncovered by claims or EHR data alone.
— With access to over 28m patients with claims and EHR data, we provide you clinical and cost data for difficult to find sub-populations around rare disease and targeted therapies.
— Our EHR and claims data also links with our National Health and Wellness Survey (NHWS), with PROs in the US. This linkage allows evidence from the patient perspective that may not be found via other means.

Global

Oracle Life Sciences National Health and Wellness Survey (NHWS)
Is a unique data asset with more than 2.5 million* survey respondents (age 18+) that allows you to conduct Patient Reported Outcomes (PRO)-based studies across (US, Europe, Brazil, JAPAC) without doing prospective surveys.
— PRO health survey including broad and therapeutic specific outcome measures
— PRO data on more than 200 conditions*/segments
— More than 50,000 variables collected annually
— Ability to recontact respondents

*Total across all countries since the survey inception

Copyright © 2024 Oracle and/or its affiliates. All rights reserved.
France
National claims database
Provides a comprehensive picture of the healthcare system in this European market.
— More than 66 million lives per year
— Nationally representative, covering 98% of the French population
— Longitudinal data for Inpatient, outpatient and home healthcare settings
— Epidemiology, healthcare resource use, treatment patterns, clinical, economic disease burden, death and causes of death
— Potentially linkable with external sources at the patient level

Asia-Pacific, the Middle East and LATAM
Oracle Life Sciences works with different local sources to bring the best data to these dynamic regions. We provide information across multiple therapeutic areas that can be used to provide evidence for meet different research requirements.
— Japan
— China
— Israel
— South Korea
— Taiwan
— Mexico
— Colombia
— Brazil

Germany
Two German pool of sickness funds
Comprehensive claims databases, allows for a wide understanding of specific conditions or products and for comparative effectiveness and safety outcome analysis.
— Fast access and with excellent geographic distribution
— 5.6 million and 4.5 million insured persons
— Representative of German insured population
— Inpatient and outpatient data
— Longitudinal data
— Epidemiology, healthcare resource use, treatment patterns, clinical and economic disease burden

About Oracle Life Sciences
Oracle Life Sciences is a leader in cloud technology, pharmaceutical research, and consulting, trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance, throughout the therapeutic development lifecycle, including pre- and post-drug launch activities. With more than 20 years’ experience, Oracle Life Sciences is committed to supporting clinical development and leveraging real-world evidence to deliver innovation and accelerate advancements – empowering the Life Sciences industry to improve patient outcomes. Learn more at oracle.com/lifesciences.